Comparison of Serum Hemagglutinin and Neuraminidase Inhibition Antibodies After 2010–2011 Trivalent Inactivated Influenza Vaccination in Healthcare Personnel

Details

• Alternative Title:
  Open Forum Infect Dis
• Personal Author:
  Laguio-Vila, Maryrose R. ; Thompson, Mark G. ; Reynolds, Sue ; Spencer, Sarah M. ; Gaglani, Manjusha ; Naleway, Allison ; Ball, Sarah ; Bozeman, Sam ; Baker, Steven ; Martínez-Sobrido, Luis ; Levine, Min ; Katz, Jackie ; Fry, Alicia M. ; Treanor, John J.
• Description:
  Background.  Most inactivated influenza vaccines contain purified and standardized hemagglutinin (HA) and residual neuraminidase (NA) antigens. Vaccine-associated HA antibody responses (hemagglutination inhibition [HAI]) are well described, but less is known about the immune response to the NA. Methods.  Serum of 1349 healthcare personnel (HCP) electing or declining the 2010-2011 trivalent-inactivated influenza vaccine ([IIV3], containing A/California/7/2009 p(H1N1), A/Perth/16/2009 [H3N2], B/Brisbane/60/2008 strains) were tested for NA-inhibiting (NAI) antibody by a modified lectin-based assay using pseudotyped N1 and N2 influenza A viruses with an irrelevant (H5) HA. Neuraminidase-inhibiting and HAI antibody titers were evaluated approximately 30 days after vaccination and end-of-season for those with polymerase chain reaction (PCR)-confirmed influenza infection. Results.  In 916 HCP (68%) receiving IIV3, a 2-fold increase in N1 and N2 NAI antibody occurred in 63.7% and 47.3%, respectively. Smaller responses occurred in HCP age >50 years and those without prior 2009-2010 IIV3 nor monovalent A(H1N1)pdm09 influenza vaccinations. Forty-four PCR-confirmed influenza infections were observed, primarily affecting those with lower pre-exposure HAI and NAI antibodies. Higher pre-NAI titers correlated with shorter duration of illness for A(H1N1)pdm09 virus infections. Conclusions.  Trivalent-inactivated influenza vaccine is modestly immunogenic for N1 and N2 antigens in HCP. Vaccines eliciting robust NA immune responses may improve efficacy and reduce influenza-associated morbidity.
• Subjects:
  Antibody Hemagglutinin-inhibition Influenza Major Articles Neuraminidase-inhibition Vaccine
• Source:
  Open Forum Infect Dis. 2014; 2(1).
• Document Type:
  Journal Article
• Volume:
  2
• Issue:
  1
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:d5c7f92024cdfdb8f66d9d25c8c613f2b94e71a14c0113e37e6b9646fb1bf2f4
• Download URL:
  https://stacks.cdc.gov/view/cdc/30613/cdc_30613_DS1.pdf
• File Type:
  [PDF - 228.12 KB ]